Testing short-term versus long-term medication for advanced prostate cancer

Plain-English translation of NCT05956639 on ClinicalTrials.gov ↗ · Source last updated July 2023 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a medication called Rezvilutamide in men with advanced prostate cancer that has spread to bones or other organs. Researchers want to find out whether taking this medication for 6 months alongside standard hormone therapy and chemotherapy works just as well as taking it for a longer time. The goal is to help doctors understand the best length of treatment while managing side effects.

Advanced prostate cancer that has spread is serious, but new medications are improving treatment options. This trial exists to figure out whether patients can benefit from shorter treatment periods with this medication, which might mean fewer side effects and a better quality of life, while still controlling their cancer effectively.

Do you qualify?

You likely qualify if…

you are at least 18 years old and male
you have been diagnosed with prostate cancer that has spread to at least 4 bone sites (with at least one outside the pelvis or spine) or to organs like the lungs or liver
you are in good enough overall health to handle chemotherapy and hormone therapy (performance status 0–1)
you are able and willing to stay on hormone therapy throughout the study period
your blood counts, liver function, and kidney function are at safe baseline levels for this treatment
you have signed an informed consent form and understand the study requirements

You likely don't qualify if…

you have received chemotherapy, hormone therapy, or advanced prostate cancer drugs (like enzalutamide, apalutamide, or abiraterone) before, unless you had up to 3 months of hormone therapy with no cancer progression beforehand
you are currently taking second-generation androgen receptor antagonists or drugs that block testosterone production for prostate cancer
you have received certain medications like 5-alpha-reductase inhibitors, estrogens, or systemic corticosteroids within 4 weeks before starting the trial
you have prostate cancer with neuroendocrine or small cell features
your heart's pumping function (left ventricular ejection fraction) is below 50%

What participation looks like

If you qualify, you will be randomly assigned to receive either 6 months or a longer course of Rezvilutamide combined with standard hormone therapy and 6 cycles of chemotherapy (docetaxel). Throughout the study, you will have regular clinic visits to receive treatment, have blood tests, imaging scans, and assessments of your symptoms and quality of life. The trial will track how well the cancer responds and monitor your overall health and side effects over time.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Testing short-term versus long-term medication for advanced prostate cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)